Skip to main content

Physician Search

 


Displaying 1 - 10 of 16

Characterization of Chronic and Unremitting Symptoms in Long Term Survivors of Head and Neck Cancer

Head/Neck

Head/Neck
N/A
Murphy, Barbara
VICCSUPP1488

Cancer Patient Safety Learning Laboratory (CaPSLL): Preventing Clinical Deterioration in Outpatients

Multiple Cancer Types

Head/Neck, Lung
N/A
Weinger, Matthew
VICCMD1998

Impact of DHT on Swallowing Physiology in HNCa Patients

Head/Neck

Head/Neck
N/A
Topf, Michael
VICCHN2102

Phase I/II Trial of Gabapentin plus Ketamine for Prevention and Treatment of Acute and Chronic Pain in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation.

Multiple Cancer Types

Head/Neck, Phase I
I/II
Lockney, Natalie
NCT05156060
VICCHNP2173

Head and Neck Tumor Tissue Repository and Clinical Database

Head/Neck

Head/Neck
N/A
Rosenthal, Eben
NCT00898638
VICCHN0356

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation or Given by Itself Compared to the Usual Treatment of Chemotherapy with Radiation after Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Head/Neck

This phase II trial studies the effect of pembrolizumab in combination with radiation therapy or pembrolizumab alone compared to the usual approach (chemotherapy plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Chemotherapy drugs, such as cisplatin and carboplatin kill tumor cells by stopping them from dividing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab in combination with radiation therapy or pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Head/Neck
II
Not Available
NCT04671667
ECOGHNEA3191

A Phase 1 Study in Patients With HPV16+ Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

Multiple Cancer Types

This is a multi-center, open-label, phase 1 dose escalation and expansion study evaluating the safety, anti-tumor effect, and immunogenicity of CUE-101 as monotherapy treatment in second line or CUE-101 Combination Therapy with Pembrolizumab in first line patients with HPV16+ Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Head/Neck, Phase I
I
Gibson, Mike
NCT03978689
VICCPHI1981

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Multiple Cancer Types

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas. The study will have three parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with sasanlimab works to treat solid tumors.
Gastric/Gastroesophageal, Head/Neck, Lung, Non Small Cell, Ovarian, Phase I
I
Crispens, Marta
NCT04254107
VICCPHI2125

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head / Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Head/Neck

A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy
Head/Neck
III
Mannion, Kyle
NCT03769506
VICCHN1927

Testing of the Body Image after Head and Neck Cancer Treatment Program

Head/Neck

This clinical trial determines if a if a web-based educational program, The Body Image after Head and Neck Cancer Treatment Program, is feasible and acceptable to patients who have been treated for head and neck cancer and have body image concerns. This program may provide a low-cost, easily accessible way for head and neck cancer survivors to address and navigate through body image concerns after treatment.
Head/Neck
N/A
Rhoten, Bethany
NCT04830488
VICCHN2123